.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Federal Trade Commission
Baxter
Argus Health
Farmers Insurance
Fish and Richardson
Accenture
Deloitte
AstraZeneca

Generated: December 17, 2017

DrugPatentWatch Database Preview

OLUX Drug Profile

« Back to Dashboard

When do Olux patents expire, and when can generic versions of Olux launch?

Olux is a drug marketed by Mylan Pharms Inc and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in OLUX is clobetasol propionate. There are thirteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
Drug patent expirations by year for OLUX

Pharmacology for OLUX

Medical Subject Heading (MeSH) Categories for OLUX

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms IncOLUXclobetasol propionateAEROSOL, FOAM;TOPICAL021142-001May 26, 2000AB1RXYesYes► Subscribe► Subscribe► Subscribe
Mylan Pharms IncOLUX Eclobetasol propionateAEROSOL, FOAM;TOPICAL022013-001Jan 12, 2007AB2RXYesYes► Subscribe► SubscribeY► Subscribe
Mylan Pharms IncOLUX Eclobetasol propionateAEROSOL, FOAM;TOPICAL022013-001Jan 12, 2007AB2RXYesYes► Subscribe► SubscribeY► Subscribe
Mylan Pharms IncOLUX Eclobetasol propionateAEROSOL, FOAM;TOPICAL022013-001Jan 12, 2007AB2RXYesYes► Subscribe► SubscribeY► Subscribe
Mylan Pharms IncOLUX Eclobetasol propionateAEROSOL, FOAM;TOPICAL022013-001Jan 12, 2007AB2RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OLUX

Drugname Dosage Strength RLD Submissiondate
clobetasol propionateEmulsion Foam0.05%Olux-E2/25/2010
clobetasol propionateTopical Foam0.05%Olux6/27/2005

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Julphar
Fish and Richardson
UBS
Farmers Insurance
Medtronic
McKinsey
Federal Trade Commission
Argus Health
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot